Clinical trials: First Line Treatment
Cholangiocarcinoma
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them…
- Trial name
- EPIC (NCT02452970)
- Testing
- RRx-001, Gemcitabine and cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EpicentRx, Inc.
Carcinoma, Small Cell
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer.
- Trial name
- NCT00129974
- Testing
- pemetrexed and gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tufts Medical Center
Metastatic Non-squamous Non Small Cell Lung Cancer
Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)
This is a randomized, open-label, multicenter, phase II study to compare a triplet combination of CBP501, pemetrexed and cisplatin with pemetrexed/cisplatin when administered to patients with locally advanced (stage IIIB with…
- Trial name
- CBP08-02 (NCT00942825)
- Testing
- CBP501 + Cisplatin + Pemetrexed, Cisplatin + Pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 195 people
- Sponsor
- CanBas Co. Ltd.
Cervical Cancer
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based…
- Trial name
- NCT03635567
- Testing
- Pembrolizumab, Paclitaxel, Cisplatin
- Where
- 149 sites in United States, Argentina and 17 more
- Volunteers
- 617 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Urothelial Carcinoma
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
The purpose of this study is to assess the safety and efficacy of avelumab in combination with other anti-tumor agents as a maintenance treatment in participants with bladder cancer.
- Trial name
- NCT05327530
- Testing
- Avelumab, Sacituzumab Govitecan (SG), M6223
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 256 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Schizophrenia, Schizophrenia-related Psychotic Disorder
A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six…
- Trial name
- NCT02006628
- Testing
- GWP42003
- Where
- 14 sites in Poland, Romania and 1 more
- Volunteers
- 88 people
- Sponsor
- Jazz Pharmaceuticals
Hepatocellular Carcinoma
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of Advanced Hepatocellular Carcinoma.
- Trial name
- NCT02576509
- Testing
- Nivolumab, Sorafenib
- Where
- 138 sites in United States, Australia and 20 more
- Volunteers
- 743 people
- Sponsor
- Bristol-Myers Squibb
Aspergillosis
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive…
- Trial name
- NCT00531479
- Testing
- voriconazole, anidulafungin
- Where
- 107 sites in United States, Australia and 22 more
- Volunteers
- 459 people
- Sponsor
- Pfizer
Head and Neck Cancer
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN).
- Trial name
- NCT01009346
- Testing
- RAD001, Cetuximab, Cisplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Idiopathic Thrombocytopenic Purpura
A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)
This study will compare the efficacy, safety, and pharmacokinetics of standard treatment versus standard treatment plus MabThera in patients with ITP.
- Trial name
- NCT00770562
- Testing
- rituximab, Dexamethasone
- Where
- 22 sites in Italy
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
This multicenter, open-label, single-arm, Phase IIIb study will evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane (docetaxel, paclitaxel or nab-paclitaxel) in first-line…
- Trial name
- PERUSE (NCT01572038)
- Testing
- Docetaxel, Nab-paclitaxel, Paclitaxel
- Where
- 299 sites in Algeria, Argentina and 37 more
- Volunteers
- 1,436 people
- Sponsor
- Hoffmann-La Roche
Advanced Adult Hepatocellular Carcinoma
Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
The aim of this study is to determine the safety and efficacy of cabozantinib in the management of unresectable or metastatic hepatocellular carcinoma (HCC) with underlying Child-Pugh class B cirrhosis.
- Trial name
- NCT04497038
- Testing
- Cabozantinib
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hypertension
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
To demonstrate that the fixed dose combination of telmisartan and amlodipine is more effective in lowering blood pressure.
- Trial name
- NCT00877929
- Testing
- Telmisartan 80, Amlodipine 10
- Where
- 65 sites in United States, Argentina and 7 more
- Volunteers
- 706 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Metastatic Breast Cancer
Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
- Trial name
- NCT00403130
- Testing
- Gemcitabine, Paclitaxel, Bevacizumab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Albert Fisher
Multiple Myeloma
Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma
The goal of this proposal is to develop a more effective and better tolerated regimen. Ixazomib appears to have greater activity than bortezomib with less peripheral neuropathy.
- Trial name
- NCT02412228
- Testing
- Ixazomib, Cyclophosphamide, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- John L. Reagan
Metastatic Colorectal Cancer
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer
One of the treatments generally used to treat this disease is a chemotherapy called FOLFIRI. The purpose of this study is to improve the efficacy of the chemotherapy by adding a protein, similar to immunoglobulins, aflibercept…
- Trial name
- NCT02181556
- Testing
- FOLFIRI Protocol, Aflibercept Injection
- Where
- 8 sites in France
- Volunteers
- 41 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Lymphoma, Follicular
A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma
This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a…
- Trial name
- NCT02569996
- Testing
- Rituximab
- Where
- 21 sites in Hungary
- Volunteers
- 124 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
This is a single-arm, single-center, open-label trial of pembrolizumab (MK-3475) in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination…
- Trial name
- NCT02589496
- Testing
- pembrolizumab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Samsung Medical Center
Breast Cancer
XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer.
- Trial name
- NCT01777945
- Testing
- capecitabine, docetaxel
- Where
- 14 sites in Hungary
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche